

GLAXOSMITHKLINE PLC

Form 6-K

April 14, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 2015

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging  
Managerial Responsibility or Connected Persons

In accordance with DTR 3.1.4R(1)(a) GlaxoSmithKline plc ('GSK') was advised on 13 April 2015, of changes in the interests of the following Directors and Persons Discharging Managerial Responsibility, following increases in their notional interests in Ordinary Shares and American Depositary Shares (ADSs), at a price of 1591.00 pence per Ordinary Share and \$47.41 per ADS, following the re-investment of dividends paid on Ordinary Shares and ADSs held in the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.

Director/PDMR	Number of Ordinary Shares acquired under personal contribution element of the plan	Number of Ordinary Shares acquired under the matching element of the plan (GSK contribution)
Sir Andrew Witty	1,803	1,803
Mr S Dingemans	687	687
Mr R G Connor	358	358
Mr N Hirons	77	77
Mr S A Hussain	307	307
Mr D S Redfern	384	384
Ms C Thomas	264	264
Mr P C Thomson	129	129
Dr P J T Vallance	922	922
Ms E Walmsley	542	542

Director/PDMR	Number of ADSs acquired under personal contribution element of the plan	Number of ADSs acquired under the matching element of the plan (GSK contribution)
Dr M M Slaoui	713	713
Mr W C Louv	183	183
Mr D E Troy	301	301

V A Whyte  
Company Secretary  
14 April 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 14, 2015

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc